Cart
sales@molnova.com
Sultosilic acid piperazine salt
CAS No. 57775-27-6
Sultosilic acid piperazine salt( —— )
Catalog No. M34434 CAS No. 57775-27-6
Sultosilic acid piperazine salt (A-585) is a novel lipid-lowering compound that can be used to study type IIb familial combined hyperlipidemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 357 | Get Quote |
|
| 5MG | 541 | Get Quote |
|
| 10MG | 775 | Get Quote |
|
| 25MG | 1178 | Get Quote |
|
| 50MG | 1619 | Get Quote |
|
| 100MG | 2142 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSultosilic acid piperazine salt
-
NoteResearch use only, not for human use.
-
Brief DescriptionSultosilic acid piperazine salt (A-585) is a novel lipid-lowering compound that can be used to study type IIb familial combined hyperlipidemia.
-
DescriptionSultosilic acid piperazine salt (A-585) is a novel lipid-lowering compound that can be used to study type IIb familial combined hyperlipidemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number57775-27-6
-
Formula Weight430.5
-
Molecular FormulaC17H22N2O7S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(=O)(O)C1=CC(OS(=O)(=O)C2=CC=C(C=C2)C)=CC=C1O.N1CCNCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Calmodulin-Dependent...
Calmodulin-Dependent Protein Kinase II (281-309) is a synthetic peptide that can be phosphorylated at Thr286 by PKC and inhibits CaM kinase II (IC50 = 80 nM).
-
Picolinamide
Picolinamide is found to be a strong inhibitor of poly (ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
